Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01711879
Other study ID # 12-1526
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2013
Est. completion date October 2015

Study information

Verified date February 2022
Source University of Colorado, Denver
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This 52 week study will assess the use of intravitreal aflibercept injections in patients with neovascular glaucoma (NVG) compared to standard of care panretinal photocoagulation. The investigators hypothesize that the neovascularization of the iris and angle present in neovascular glaucoma will resolve more quickly in eye treated with intravitreal aflibercept injection alone and result in increased comfort and preservation of visual field as compared to current standard of care utilizing pan-retinal photocoagulation. The advantages to intravitreal aflibercept injection use could include resolution of NVI/NVA (neovascularization of the iris/neovascularization of the angle) leading to quicker pain relief and quicker lowering of IOP (intraocular pressure).


Description:

The two arms of this study will compare current common practice (initial intravitreal anti-VEGF (vascular endothelial growth factor) to study treatment (VEGF) injection only) for 52 weeks. This single center study will consist of 20 patients with NVG. Patients will be randomized to: - Group A: A single injection of 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by standard of care laser with observation for a total of 52 weeks. or - Group B: 2mg (0.05ml) intravitreal aflibercept injection at baseline followed by two additional injections at 4 weeks and 8 weeks, then every 8 weeks for a total of 52 weeks. Clinical assessment will include pain assessment (Universal Pain Scale), best corrected visual acuity (ETDRS), ophthalmic examination, anterior segment assessment including number of clock-hours of NVI/NVA, gonioscopy, anterior segment photography, visual field test (Humphrey SITA- Standard 24-2), optic nerve OCT (Zeiss Cirrus Optic Disc Cube 200x200), macular OCT (Cube scan 512 x 128 and 5 Line Raster), fluorescein angiography (initial iris phase followed by standard retinal angiography), and concurrent medical/ocular medications. Qualitative assessment of neovascularization will be made by the investigator based on comparison to baseline angiography.


Recruitment information / eligibility

Status Completed
Enrollment 7
Est. completion date October 2015
Est. primary completion date October 2015
Accepts healthy volunteers No
Gender All
Age group 21 Years to 90 Years
Eligibility Inclusion Criteria: - Patients with a diagnosis of neovascular glaucoma (Stage I-II) - Individuals who are ages 21-90 years old; male or female of any race - Presence of neovascularization of the iris and/or angle - At least 90 degrees of "unzipped" anterior chamber angle as noted by gonioscopy. (a "zipped angle is the term used for a drainage angle that is slowly closing due to scar tissue from the neovascularization process) - Visual acuity of light perception or better in the study eye - Willing and able to comply with clinic visits and study-related procedures - Provide signed informed consent Exclusion Criteria: - Use of intravitreal anti-VEGF agents in the study eye in the past 3 months. - Full PRP in the study eye - Prior vitrectomy in the study eye - Prior trabeculectomy or other filtration surgery in the study eye - Active ocular or periocular infection in the study eye - Ocular conditions (Cataract or vitreous hemorrhage) that might require surgery in next 12 months - Allergy to fluorescein dye - Any past use of systemic anti-VEGF medication - Myocardial infarction within 6 months prior to study enrollment - Stroke within 6 months prior to study enrollment - Pregnant or breast-feeding women - Sexually active men or women of childbearing potential who are unwilling to practice adequate contraception during the study

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aflibercept
Details covered in arm description

Locations

Country Name City State
United States Rocky Mountain Lions Eye Institute Aurora Colorado

Sponsors (1)

Lead Sponsor Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the incidence of adverse events 2 year
Primary Severity of Adverse Events Assess the safety profile of repeated intravitreal aflibercept injections in patients with NVG by evaluating the severity of adverse events 2 year
Secondary Rate and Extent of Resolution of Neovascularization Compare between Groups A and B the Rate and extent of resolution of neovascularization in patients with NVG Stages 1 & 2. 1 year
Secondary Intraocular Pressure (mmHg) at Baseline Intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B Baseline
Secondary Intraocular Pressure (mmHg) at Week 52 Mean intraocular pressure(mmHg) as measured by Goldmann applanation tonometry between groups A and B Week 52
Secondary Number of Patients Losing > 5 Letters on Visual Acuity in Each Group A and Group B Comparison between patients, groups A and B, that lost > 5 letters on visual acuity Baseline to Week 52
Secondary Number of Patients in Each, Group A and Group B, Gaining > 5 Letters on Visual Acuity Comparison of patients in each, group A and group B, that gained > 5 letters on visual acuity Baseline to Week 52
Secondary Visual Acuity at Baseline Comparison of visual acuity between groups A and B Baseline
Secondary Visual Acuity at Week 52 Comparison of visual acuity at Week 52 between groups A and B Week 52
Secondary Comparison of the Visual Field Between Groups Comparison of the Visual field s measured by HVF 24-2 SITA Standards between groups A and B 1 year
Secondary Measure of the Optical Coherence Tomography(OCT) Outcomes Evaluation of the Optical Coherence Tomography(OCT) outcomes (average retinal nerve fiber layer(RNFL) and central macular thickness), Compared between groups A and B. Baseline to Week 52
Secondary Number of Patients With Need for Surgical Intervention Comparison between groups A and B and the need for surgical intervention in both arms during the follow-up period 1 year
Secondary Number of Participants With Need for Additional IOP Lowering Medications Comparison between groups A and B for the need of additional IOP lowering medications 1 year
Secondary Extent of Resolution of Neovascularization Between Groups Comparison of groups A and B and the extent of resolution of neovascularization in patients with NVG Stages 1 & 2 1 year
Secondary Evaluation of the Average Retinal Nerve Fiber Layer (RNFL) Comparison between groups A and B of the average retinal nerve fiber layer (RNFL) as measured by Optical Coherence Tomography (OCT) 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00491712 - Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection N/A
Recruiting NCT04519619 - Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)
Completed NCT01370135 - Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma N/A
Completed NCT04970251 - Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma N/A
Completed NCT02805257 - Ahmed Glaucoma Valve Surgery With Mitomycin-C Phase 2
Recruiting NCT02067013 - Analysis of Aqueous and Vitreous Humor Phase 2
Completed NCT00524758 - Oculusgen (Ologen) Glaucoma MMC Control in Estonia Phase 3
Withdrawn NCT00727038 - Lucentis for New Onset Neovascular Glaucoma Phase 1/Phase 2
Not yet recruiting NCT02947867 - Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG Phase 2/Phase 3
Terminated NCT02260219 - Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma N/A
Withdrawn NCT00441181 - Effects of Travoprost on Neovascular Glaucoma N/A
Completed NCT01051583 - Avastin as an Adjunct to Diode Laser in the Treatment of Neovascular Glaucoma Phase 2
Completed NCT05156021 - A Study on the Treatment Strategy of NVG Secondary to PDR N/A
Terminated NCT01301378 - Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube N/A
Not yet recruiting NCT05316142 - Any Unique Identifier Assigned to the Protocol by the Sponsor N/A
Recruiting NCT04844619 - KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial Phase 1
Completed NCT03154892 - The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma N/A